Despite tremendous progress in the past decade, the complex and heterogeneous nature of
cancer complicates efforts to identify new therapies and therapeutic combinations that …

Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD)
molecules that induce degradation by the ubiquitin-proteasome system (UPS) offer new …

The availability of a large amount of multiomics data enables data-driven discovery studies
on cancers. High-throughput data on mutations, gene/protein expression, immune scores …

Molecular-glue degraders are small molecules that induce a specific interaction between an
E3 ligase and a target protein, resulting in the target proteolysis. The discovery of molecular …

The efficacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative
healthy tissues. A cancer-specific dependency on the microtubule motor protein KIF18A …

Undermining transcriptional addiction, the dependence of cancers on selected
transcriptional programs, is critically important for addressing cancers with high unmet …

Although long noncoding RNAs (lncRNAs) dominate the transcriptome, their functions are
largely unexplored. The extensive overlap of lncRNAs with coding and regulatory …

Anticipating and understanding cancers' need for specific gene activities is key for novel
therapeutic development. Here we utilized DepMap, a cancer gene dependency screen, to …

Alternative splicing is crucial for cancer progression and can be targeted pharmacologically,
yet identifying driver exons genome-wide remains challenging. We propose identifying such …

Combination chemotherapy is crucial for successfully treating cancer. However, the
enormous number of possible drug combinations means discovering safe and effective …